Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS -mutant advanced non-small cell lung cancer: the SELECT -1 randomized clinical trial.

2.50
Hdl Handle:
http://hdl.handle.net/10541/620404
Title:
Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS -mutant advanced non-small cell lung cancer: the SELECT -1 randomized clinical trial.
Authors:
Jänne, P; van den Heuvel, M; Barlesi, F; Cobo, M; Mazieres, J; Crinò, L; Orlov, S; Blackhall, Fiona H ( 0000-0001-8716-3395 ) ; Wolf, J; Garrido, P; Poltoratskiy, A; Mariani, G; Ghiorghiu, D; Kilgour, E; Smith, P; Kohlmann, A; Carlile, D; Lawrence, D; Bowen, K; Vansteenkiste, J
Abstract:
There are no specifically approved targeted therapies for the most common genomically defined subset of non-small cell lung cancer (NSCLC), KRAS-mutant lung cancer.
Affiliation:
Lowe Center for Thoracic Oncology and the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusetts
Citation:
Selumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS -mutant advanced non-small cell lung cancer: the SELECT -1 randomized clinical trial. 2017, 317 (18):1844-1853 JAMA
Journal:
JAMA
Issue Date:
2017
URI:
http://hdl.handle.net/10541/620404
DOI:
10.1001/jama.2017.3438
PubMed ID:
28492898
Type:
Article
Language:
en
ISSN:
1538-3598
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorJänne, Pen
dc.contributor.authorvan den Heuvel, Men
dc.contributor.authorBarlesi, Fen
dc.contributor.authorCobo, Men
dc.contributor.authorMazieres, Jen
dc.contributor.authorCrinò, Len
dc.contributor.authorOrlov, Sen
dc.contributor.authorBlackhall, Fiona Hen
dc.contributor.authorWolf, Jen
dc.contributor.authorGarrido, Pen
dc.contributor.authorPoltoratskiy, Aen
dc.contributor.authorMariani, Gen
dc.contributor.authorGhiorghiu, Den
dc.contributor.authorKilgour, Een
dc.contributor.authorSmith, Pen
dc.contributor.authorKohlmann, Aen
dc.contributor.authorCarlile, Den
dc.contributor.authorLawrence, Den
dc.contributor.authorBowen, Ken
dc.contributor.authorVansteenkiste, Jen
dc.date.accessioned2017-06-29T10:15:56Z-
dc.date.available2017-06-29T10:15:56Z-
dc.date.issued2017-
dc.identifier.citationSelumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS -mutant advanced non-small cell lung cancer: the SELECT -1 randomized clinical trial. 2017, 317 (18):1844-1853 JAMAen
dc.identifier.issn1538-3598-
dc.identifier.pmid28492898-
dc.identifier.doi10.1001/jama.2017.3438-
dc.identifier.urihttp://hdl.handle.net/10541/620404-
dc.description.abstractThere are no specifically approved targeted therapies for the most common genomically defined subset of non-small cell lung cancer (NSCLC), KRAS-mutant lung cancer.en
dc.language.isoenen
dc.rightsArchived with thanks to JAMAen
dc.titleSelumetinib plus docetaxel compared with docetaxel alone and progression-free survival in patients with KRAS -mutant advanced non-small cell lung cancer: the SELECT -1 randomized clinical trial.en
dc.typeArticleen
dc.contributor.departmentLowe Center for Thoracic Oncology and the Belfer Center for Applied Cancer Science, Dana-Farber Cancer Institute, Boston, Massachusettsen
dc.identifier.journalJAMAen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.